Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Two Part Study to Separately Evaluate the Effect of 4-week Treatment With GW501516X Relative to Placebo on Cardiac Energetics in a Randomized, Single-blind, Repeat Dose, Parallel Group Design in Healthy Male Subjects

NCT00318617 is registered in ClinicalTrials.gov with GlaxoSmithKline as lead sponsor.

NCT NCT00318617
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00318617 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Two Part Study to Separately Evaluate the Effect of 4-week Treatment With GW501516X Relative to Placebo on Cardiac Energetics in a Randomized, Single-blind, Repeat Dose, Parallel Group Design in Healthy Male Subjects
Lead sponsor
GlaxoSmithKline
Phase
Observational
Overall status
Terminated
Start date
December 31, 2005
Completion date
Not reported
Enrollment
30
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

dyslipidaemias, heart failure